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 Introduction 
 Intrauterine growth restriction (IUGR) is a major 
cause of fetal morbidity and mortality. It has already been 
shown that fetal exposure to high glucocorticoid levels 
during pregnancy results in a low birth weight  [1, 2] , as-
sociated with higher risk for cardiovascular and meta-
bolic disorders such as hypertension and diabetes type 2 
in adult life (fetal programming)  [3, 4] . Moreover, new-
borns after IUGR show a higher blood glucocorticoid lev-
el than normally developed infants with corresponding 
gestational age  [5] .
 In human pregnancy, maternal circulating cortisol 
concentrations are 5–10 times higher than fetal concen-
trations  [6, 7] . This difference is maintained by the 11  -
hydroxysteroid dehydrogenase enzyme (11  -HSD). Two 
isoforms of 11  -HSD exist: the 11  -HSD1 is NADP(H)-
dependent and catalyzes the conversion of cortisol to cor-
tisone and vice versa, whereas the 11  -HSD2 requires 
NAD and has (in vivo) only oxidase (dehydrogenase) ac-
 Key Words 
 11  -Hydroxysteroid dehydrogenase   Placenta   Fetal 
membranes   Intrauterine growth restriction 
 Abstract 
 Objectives: To study the expression and the function of the 
11  -hydroxysteroid dehydrogenase enzyme 1 (11  -HSD1) 
and 2 (11  -HSD2) in placenta and the fetal membranes from 
pregnancies with intrauterine growth restriction (IUGR) and 
from controls.  Methods: Amnion, chorion, decidua and cot-
yledon were separated from placenta; mRNA was analyzed 
by TaqMan real-time technology and proteins by Western 
blot; enzyme activities were measured by the conversion of 
 3 H-cortisol to  3 H-cortisone and vice versa.  Results: Predom-
inant mRNA expression (p  ! 0.001) was found for 11  -HSD1 
in chorion and for 11  -HSD2 in decidua and cotyledon. In 
pregnancies with IUGR, 11  -HSD1 was upregulated in cho-
rion (mean   Ct 11  -HSD:18S mRNA 193.5 vs. 103.0 in controls 
respectively, p  ! 0.05) and 11  -HSD2 was downregulated in 
decidua (mean   Ct 11  -HSD2: 18S mRNA 0.18 vs. 15.88 in 
controls respectively, p  ! 0.05). 11  -HSD1 protein levels were 
reduced in amnion and 11  -HSD1 and 11  -HSD2 oxidase ac-
tivity in decidua and cotyledon were reduced from pregnan-
cies with IUGR.  Conclusion: Reduced synthesis or activity of 
11  -HSD1 or 2 in cases of IUGR is shown in some but not in 
all tissues. The local mRNA expression of 11  -HSD1 in cho-
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tivity (conversion of the hormonally active cortisol to the 
inactive form cortisone)  [8, 9] . Both isoenzymes have 
been identified in human placenta. However, conflicting 
results exist on its expression (mRNA, protein) and the 
activity in human placental tissue depending on gesta-
tional age, delivery mode, cellular localization of the 
sample and preparation of the tissue: it seems that the 
11  -HSD1 is more abundant in chorion and amnion  [10, 
11] . Its reductase activity is stimulated by prostaglandins 
and may be therefore an additional regulator for the onset 
of labor and birth  [12] . Its role in fetal growth is still un-
clear, although for pregnancies with preeclampsia a re-
duced activity for 11  -HSD1 oxidase (but not for the re-
ductase form) has been found  [13] . A recent study about 
the gene expression found reduced mRNA levels for both 
the 11  -HSD1 and the 11  -HSD2 in placentae of small-
for-gestational-age neonates  [14] . The 11  -HSD2 is abun-
dant in the syncytiotrophoblast  [15] or in placental tissue 
without fetal membranes  [10] . It protects the fetus from 
high maternal cortisol level and its primary role is there-
fore that of a barrier  [16] . Additionally it protects the pla-
cental mineralcorticoid receptor in the placenta itself and 
regulates the fetal-maternal electrolyte and water trans-
port  [17] . Both functions may be associated with the reg-
ulation of fetal growth. Indeed, a reduced expression as 
well as a reduced activity for the 11  -HSD2 has been 
found in pregnancies with IUGR or preeclampsia  [13, 14, 
18–22] . Conflicting findings about the expression and ac-
tivity of both 11  -HSD isoenzymes in pregnancies with 
IUGR led us to initiate the present study. The objective 
was therefore to provide detailed information on the ex-
pression as well as on the function (activity) of the 11  -
HSD1 and 11  -HSD2 in placenta (decidua and cotyle-
don) and in the fetal membranes (amnion, chorion) from 
pregnancies with IUGR and from gestational age-matched 
normal pregnancies (controls).
 Material and Methods 
 Selection of the Patients 
 Tissue samples were taken from women with singleton preg-
nancies delivered by elective caesarean section at our department. 
All women provided written informed consent for the study 
which was approved by the local institutional review board. The 
group with IUGR consisted of 10 placentae from pregnancies 
where growth restriction was defined as gestational-related birth 
weight below the 10th centile (SGA)  [23] and/or where ultrasound 
growth rates fall without maternal pathology such as preeclamp-
sia or abnormal Doppler in umbilical artery. The control group 
(n = 12) consisted of placentae from pregnancies without growth 
restriction but with matched gestational age. Controls parallel to 
cases were recruited consecutively during 10 months. Exclusion 
criteria were: multiple pregnancy, neonatal infection, amnion in-
fection syndrome, CRP  6 5 mg/l, BMI  6 30 kg/m 2 , gestational 
diabetes, diabetes mellitus, cardiovascular diseases, neoplasia, 
hepatitis, HIV infection, nicotine, alcohol and drug abuse, and 
treatment with corticosteroids for fetal lung maturation.
 Tissue Preparation 
 Immediately after delivery a representative piece of placenta 
(20–50 g in  6 2 cm distance from the cord and the margin) was 
taken. From the fetal side, fetal membranes, i.e. amnion and cho-
rion, were separated from each other. From the maternal side the 
first grayish layer consisted of decidua tissue and the cotyledon 
consisted of villous tissue without decidua and without fetal 
membranes. Contamination with maternal blood was avoided in 
all samples. Histological and immunohistochemical character-
izations were performed to assess the purity of the isolated am-
nion, chorion and decidua. The samples of each layer (2 g) were 
snap-frozen in liquid nitrogen and ground in a metal mortar 
stored before at –80 ° C and filled up with liquid nitrogen. The 
powdered sample was stored at –80  ° C until RNA extraction and 
microsomal preparation for Western analysis of proteins and for 
activity assay.
 mRNA Expression 
 RNA Isolation 
 350 mg of the frozen powdered tissue was lysed in 350 ml lysis 
buffer (guanidine salt) and total RNA extraction was performed 
with the RNeasy Mini Kit from Qiagen AG (Hombrechtikon, 
Switzerland) according to the manufacturer’s protocol. Potential 
DNA was digested with DNase in the same kit. RNA concentra-
tion was determined with a spectrophotometer (Eppendorf Bio-
Photometer).
 Reverse Transcription to cDNA 
 Reverse Transcription System ImProm-II TM and the PCR kit 
were from Promega AG (Wallisellen, Switzerland). Agarose was 
from AppliChem GmbH (Darmstadt, Germany) and all other 
chemicals were from Sigma-Aldrich GmbH (Buchs, Switzerland). 
600 ng RNA and 1   l of primer were heated at 70  ° C for 15 min 
and cooled at 4 ° C for 5 min. 14   l of the RT master mix were 
added to the primer/RNA mix and cycled according to the man-
ufacturer’s protocol. To test if RNA extraction and RT were suc-
cessful, a PCR with   -actin was performed according to the stan-
dard manufacturer’s protocol.
 Quantitative (Real-Time) PCR 
 We used the TaqMan method  [24] already described for 11  -
HSD mRNA in placental tissue  [19, 20, 25] . The PCR reaction was 
performed with the TaqMan Universal PCR Master Mix and the 
TaqMan Gene Expression Assay Mix designed by Applied Biosys-
tems, Inc. (Foster City, Calif., USA) containing the following 
primers:  11  -HSD1 : Gene ID 3290, 77 bp, assay location 626; 
Hs00194153_m1 (NM 181755.1);  11  -HSD2: Gene ID 3291, 50 bp, 
assay location 387; Hs00388669_m1 (NM 000196.2);  18S rRNA : 
Gene ID 36162, 187 bp, assay location 60; Hs99999901 s1 (X 
03205.1). According to the manufacturer’s protocol the reaction 
was performed on a reaction plate in 20   l volume/well contain-
ing 40 ng cDNA. Measurements were done with ABI Prism 7000 
Sequence Detection System (Applied Biosystems, Inc.). All reac-
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tions were duplicated with the housekeeping gene 18S. Data were 
obtained as Ct values (the cycle number at which logarithmic PCR 
plots cross a calculated threshold line) to determine   Ct (Ct of the 
target gene – Ct of the housekeeping gene = 11  -HSD:18S). Mea-
surements were carried out in triplicates. On each plate a triplicate 
of a control cotyledon sample from 1 volunteer (always the same) 
was measured as internal standard. Final results of 11  -HSD 
mRNA were expressed as relative fold increase in   Ct mRNA of 
the target related to the   Ct of the internal standard (arbitrary 
value of 1).
 Protein 
 Microsomal Preparation 
 100 mg of the frozen powdered tissue from the four different 
sources were homogenized in four independent charges each in 
1 ml cooled TS2 buffer (NaCl 100 m M , EDTA 1 m M , EGTA 1 m M , 
MgCl 2 1 m M , sucrose 250 m M , Tris-HCl pH 7.4 20 m M ) using the 
Fast Prep technique (Bio 101 Savant Fast Prep FP120; twice 20 s, 
speed 4.0, 4 ° C). Tissue homogenates were centrifuged at 4 ° C at 
805  g for 12 min and the supernatants were used for Western blot 
analysis (and the assay of activity, see below). The protein content 
was measured by the Bradford method using a protein assay kit 
(Bio-Rad) with BSA as standard  [26] .
 Western Blot Analysis 
 We followed the principle already described by Alfaidy et al. 
 [21] with some modifications. Thawed samples from microsomal 
preparation were diluted 1: 5 (final concentration of protein 30   g) 
with Laemmli sample buffer (62.5 m M Tris-HCl pH 6.8, 25% glyc-
erol, 2% sodium dodecyl sulfate and 0.01% bromophenol blue 
(Bio-Rad Laboratories, Inc., Hercules, Calif., USA, ordered by Bio-
Rad Laboratories, Reinach, Switzerland) and heated at 100  ° C for 
5 min. Polyacrylamide gels were prepared (stacking gel 15%, sepa-
rating gel 15%). Proteins (7.5   g per lane) were separated by SDS-
PAGE and then transferred electrophoretically onto a nitrocellu-
lose membrane (Bio-Rad, Inc., USA). The Western blot was run at 
400 V for 80–90 min. Transfer was confirmed by protein visual-
ization with Ponceau S (Sigma-Aldrich). Membranes were care-
fully rinsed with distilled water. Blocking was made in 4% BSA
(4 g bovine serum albumin in 100 ml Tris-buffered saline, pH 7.5). 
Subsequently, blots on membranes were cut into halves and one-
half was incubated with primary antibodies for rabbit anti-mouse 
11  -HSD1 and rabbit anti-human 11  -HSD2 respectively (all 
from Alpha Diagnostic International, ordered by VWR Int.,
Dietikon, Switzerland) for 1 h at room temperature. Membranes 
with the same samples but without primary antibody were used 
for negative controls. Membranes were then rinsed 4 times for
5 min in Tris-buffered saline and incubated with secondary poly-
clonal rabbit antiserum conjugated with horseradish peroxidase 
(DakoCytomation, Zug, Switzerland; Ref. P 0448) for 1 h. Mem-
branes were washed 4 times, 5 min each and the antibody-antigen 
complex was detected using the Hypercasette from Amersham 
Pharmacia Biotech containing an X-ray film. A major band of 34 
kDa corresponding to the known molecular mass of 11  -HSD1 
and a second major band of 41 kDa corresponding to the molecu-
lar mass of 11  -HSD2 were clearly visible. All Blue Precision Plus 
Protein Standard (Bio-Rad, Inc., USA) was thereby used as a mark-
er and   -actin was used to control loading errors. Protein bands 
were quantified by Image J Software. Relative optical density (OD) 
units were obtained from each band by analyzing mean OD.
 Activity 
 Reagents and Supplies 
 [1,2,6,7- 3 H]cortisol (69 Ci/mmol) and [1,2,6,7- 3 H]cortisone 
(42 Ci/mmol) were purchased from Amersham Biosciences (High 
Wycombe, Bucks., UK). Nonradioactive steroids, coenzymes and 
other chemicals were obtained from Sigma-Aldrich. Thin-layer 
chromatography plates (SIL G-25 UV254) were obtained from 
Machery-Nagel GmbH (Oensingen, Switzerland).
 Frozen aliquots of the microsomal preparations were used. No 
significant change in 11  -HSD activity was detected after storage 
of frozen aliquots at –80 ° C for 4 months. Oxidase and reductase 
activities were assessed by measuring the conversion rate of 
[ 3 H]cortisol to [ 3 H]cortisone and vice versa. The method was 
modified from assays already published  [27, 28] . Reactions were 
carried out in 96-well optical PCR reaction plates (Nunc-Immu-
no TM 96 MicroWell TM Plates, Nunc, Wiesbaden, Germany). Paral-
lel assays in the same wells containing no placental homogenate 
were performed to control the spontaneous interconversion be-
tween 11-dehydro and 11-hydroxy forms of the steroids. For the 
oxidase activity (11  -HSD1 and 11  -HSD2) 10   l of the homog-
enate corresponding to 20   g of protein were incubated with 10 
  l TS2 buffer in the presence of saturating substrate ([ 3 H]cortisol 
and 5 n M cortisol) and coenzyme (400   M NADP for 11  -HSD1 
or 400   M NAD for 11  -HSD2 respectively) for 15 min at 37 ° C 
on a ThermoShaker. For the reductase activity (11  -HSD1), 10   l 
of the homogenate corresponding to 20   g of protein were incu-
bated with 10   l TS2 buffer in the presence of substrate ([ 3 H]cor-
tisone and 5 n M cortisone) and coenzyme (400   M NADPH) 
for 15 min at 37 ° C on a ThermoShaker. The reactions were 
stopped by immediate transfer of the tubes to ice, addition of 
methanol and an excess of unlabeled steroids.  3 [H]cortisol and 
[ 3 H]cortisone were separated by thin-layer chromatography and 
the radioactivity was counted using a beta counter. Activities 
were expressed as nanomoles of cortisone or cortisol respectively 
formed per milligram of microsomal protein per minute. The 
percentage conversion of cortisol to cortisone and vice versa 
should be  1 2%. Data of each layer were obtained from two inde-
pendent charges of homogenates.
 Statistics 
 For statistical analysis the program StatView 5.0.1 for Win-
dows XP was used. From data mean and standard deviation (SD), 
standard error of the mean (SE) and the median were calculated. 
Data in graphs are given mean  8 SE. Differences between the two 
groups (IUGR vs. control) were tested by the Mann-Whitney test 
(for nonparametric data) and the unpaired t test respectively (for 
log-normal distributed data). Differences between placental lay-
ers were tested by the Wilcoxon signed test and the Kruskal-Wal-
lis test (all four placental layers in one comparison). p  ! 0.05 was 
defined as significant in all tests.
 Results 
 Demography of the Volunteers 
 Most of the women with IUGR were primiparae re-
flecting the higher incidence of IUGR in primi- than in 
multiparae ( table 1 ). There were 3 pregnancies in the con-
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trol group with delivery at  ! 37.0 weeks who had idio-
pathic preterm labor without tocolysis (gestational age 34 
weeks).
 mRNA Expression 
 Both isoenzyme mRNA and 18S amplified with the 
same efficiency. No significant differences existed in the 
rRNA of the 18S housekeeping gene between the IUGR 
(Ct 16.56  8 0.15) and the control group (Ct 16.84  8 0.15; 
mean  8 SE), p = 0.19, nor within the groups between the 
layers rendering the 18S as a valid housekeeping gene for 
fetal membranes and for placental tissue. The highest ex-
pression of the 11  -HSD1 mRNA was measured in cho-
rion (p  ! 0.001 vs. amnion, decidua or cotyledon respec-
tively). The 11  -HSD2 mRNA was highly expressed in 
the decidua and in the cotyledon (p  ! 0.001 vs. amnion 
or chorion respectively); only small amounts were found 
in the fetal membranes ( table 2 ). After log transformation 
the values were log normally distributed and the 11  -
HSD1 mRNA was significantly higher than that of 11  -
HSD2 in all layers (p  ! 0.0001 and p  ! 0.005, unpaired 
t test).
 In chorion the 11  -HSD1 mRNA expression was ap-
proximately 2 times higher in IUGR (193.52  8 50.17) 
than in the control group (103.0  8 27.71 relative fold in-
crease; p  ! 0.05; Mann-Whitney test) ( fig. 1 a). No differ-
ences between pathological and normal pregnancies ex-
isted in the other layers. The 11  -HSD2 mRNA expres-
sion in decidua was significantly lower in pregnancies 
with IUGR than in normal pregnancies (0.18  8 0.10 vs. 
15.88  8 10.49 relative fold increase; p  ! 0.05) ( fig. 1 b).
Table 1. Demographic data of the volunteers
Control (n = 12) IUGR (n = 10) p
Age, years 31.484.4 (30.0) 34.086.7 (33.0) 0.3
Caucasian, n 10 10 0.48
Parity >1, n 9 2 0.01
GA at delivery, weeks 36.981.6 (37.4) 35.182.7 (35.3) 0.07
Elective caesarean section, n 12 10 1.0
Placental weight wet, g 566.7891.6 (560.0) 419.28124.2 (387.5) 0.01
Fetal weight, g 3,002.58540.9 (3,225.0) 2,005.08688.7 (2,240.0) 0.001
Fetal weight, centile 52.3827.2 (55.4) 3.683.8 (2.6) <0.0001
GA = Gestational age. Continuous values = mean 8 SD (median); numeric values = n.
Differences between the groups were tested by unpaired two-tailed t test or Fisher’s two-tailed exact test as 
indicated.
Table 2. 11-HSD1 and 11-HSD2/18S mRNA (relative units) in placental tissues from all subjects (n = 22)
Amnion Chorion Decidua Cotyledon
11-HSD1 19.51810.10
(0.11; 161.15)
144.14828.40a
(110.84; 527.45)
7.6282.21
(3.81; 35.68)
5.3482.17
(1.38; 41.54)
11-HSD2 0.0380.01
(0.005; 0.224)
0.0180.003
(0.004; 0.04)
8.7585.86b
(0.03; 106.02)
4.1683.30b
(0.39; 72.79)
pc <0.0001 <0.0001 <0.0001 <0.005
Data = mean 8 SE (median; range).
a p < 0.001 compared with amnion, decidua or cotyledon respectively tested by Wilcoxon’s signed rank 
test.
b p < 0.001 compared with amnion or chorion tested by Wilcoxon’s signed rank test.
c Differences between log values of 11-HSD1 and 11-HSD2 were tested by unpaired two-tailed t test.
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 Protein Expression 
 The 11  -HSD1 and 11  -HSD2 proteins were both 
present in all tissues ( fig. 2 ,  3 ). 11  -HSD1 levels (relative 
ODs) were reduced in pregnancies with IUGR in amnion, 
chorion and decidua but not in cotyledon; however, only 
in amnion the difference was significant (4.42  8 1.46 vs. 
8.24  8 1.16, mean  8 SE, p  ! 0.05). Levels were higher in 
chorion, decidua and cotyledon than in amnion [p  ! 0.05 
chorion vs. amnion (IUGR) and decidua vs. amnion 
(IUGR and controls); p  ! 0.001 cotyledon vs. amnion 
(IUGR and controls)]. 11  -HSD2 protein levels in IUGR 
and controls were similar. Differences in levels between 
the tissue were only found in normal pregnancies (14.56 
 8 1.75 in decidua vs. 9.54  8 1.63 in amnion, mean  8 
SE, p  ! 0.05).
 Activity 
 Oxidase Activity 
 No difference between 11  -HSD1 (NADP-dependent) 
and 11  -HSD2 (NAD-dependent) activities (nmol/mg 
protein/h) was found; however, activities were signifi-
cantly higher in decidua (2.53  8 0.83) and in cotyledon 
(2.05  8 0.57) than in amnion (0.18  8 0.12, p  ! 0.0001) 
or in chorion (0.81  8 0.29, mean  8 SE, p  ! 0.001) ( fig. 4 a). 
Oxidase activities were decreased in tissues from preg-
nancies with IUGR; it was not measurable in IUGR am-
nion samples. The difference in 11  -HSD2 (or 11  -HSD1) 
between IUGR and controls was significant in cotyledon 
(1.23  8 0.75 vs. 2.72  8 0.82 nmol/mg protein/h in con-
trols; p  ! 0.05) ( fig. 4 b).
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 Fig. 1. Mean  8 SE mRNA expression (relative fold increase in   Ct related to the   Ct of the internal standard 
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 Fig. 2. Protein expression of  a 11  -HSD1 (35 kDa) and of  b 11  -HSD2 (41 kDa) (Western blot) in amnion (A), 
chorion (Ch), decidua (D) and cotyledon (C). M was the used marker (Precision Plus Protein Standard from 
Bio-Rad).   -Actin was used to control loading errors and did not show any expression. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 8
:5
7:
13
 A
M
 11  -HSD in Human Placenta and Fetal 
Membranes from IUGR Pregnancies 
 Fetal Diagn Ther 2009;25:328–335 333
0
5
10
15
20
25
Amniona Chorion Decidua Cotyledon
*
11

-H
SD
1
(r
el
at
iv
e 
op
ti
ca
l d
en
si
ty
)
Control
IUGR
0
5
10
15
20
25
Amnionb Chorion Decidua Cotyledon
11

-H
SD
2
(r
el
at
iv
e 
op
ti
ca
l d
en
si
ty
)
Control
IUGR
a
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Amnion Chorion Decidua Cotyledon
11

-H
SD
 o
xi
d
as
e
ac
ti
vi
ty
 (n
m
ol
/m
g
/h
) 
**
*†
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Amnionb Chorion Decidua Cotyledon
*
11

-H
SD
1 
ox
id
as
e 
ac
ti
vi
ty
 ( 
  m
ol
/m
g
/h
) 
Control
IUGR
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Amnionc Chorion Decidua Cotyledon
*
11

-H
SD
2 
ox
id
as
e 
ac
ti
vi
ty
 ( 
   
m
ol
/m
g
/h
) 
Control
IUGR
 Fig. 3. Mean  8 SE protein expression from Western blot (relative OD) in fetal membranes and placenta from 
pregnancies with IUGR (n = 10) vs. normal pregnancies (controls, n = 12).  a 11  -HSD1,  b 11  -HSD2.  * p  ! 0.05 
IUGR vs. controls in amnion. 
 Fig. 4.  a Mean  8 SE. 11  -HSD oxidase activity (nmol/mg pro-
tein/h) in microsomal preparation of fetal membranes and pla-
centa from all pregnancies (n = 22).  * p  ! 0.01 amnion vs. chorion, 
 † p  ! 0.0001 amnion vs. decidua or cotyledon, and  * * p  ! 0.001 
chorion vs. decidua or cotyledon, respectively. There was no dif-
ference between oxidase activity of 11  -HSD1 and that of 11  -
HSD2.  b Mean  8 SE 11  -HSD1 oxidase activity (nmol/mg pro-
tein/h) in microsomal preparation of fetal membranes and pla-
centa from pregnancies with IUGR (n = 10) vs. normal pregnancies 
(controls, n = 12).  c Mean  8 SE. 11  -HSD2 oxidase activity 
(nmol/mg protein/h) in microsomal preparation of fetal mem-
branes and placenta from pregnancies with IUGR (n = 10) vs. 
normal pregnancies (controls, n = 12). Oxidase activity was not 
measurable in IUGR amnion samples.  * p  ! 0.05 IUGR vs. con-
trols in cotyledon. 
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 Reductase Activity 
 The 11  -HSD1 (NADPH)-dependent reductase activ-
ity was not measurable in fetal membranes (amnion and 
chorion) or was too low (conversion of cortisone to corti-
sol  ! 2% in decidua, cotyledon); no comparison between 
pregnancies with IUGR and controls was therefore pos-
sible (data not shown).
 Comment 
 To our knowledge the present study may be the first 
focusing on all elements (mRNA, protein, activity) of 
both isoenzymes, the 11  -HSD1 and the 11  -HSD2 in 
placenta and in fetal membranes from normal and IUGR 
pregnancies. We demonstrated a significantly higher 
mRNA expression of 11  -HSD1 than of 11  -HSD2 in all 
four tissues. The 11  -HSD1 mRNA was abundant in cho-
rion whereas the protein levels as well as the oxidase ac-
tivity were more abundant in placenta than in fetal mem-
branes. Therefore, we found little concordance between 
mRNA and protein expression although all analyses were 
performed from the same samples and by the same ana-
lyzers. Our data confirm the apparent discrepancy of the 
results from previous studies: The first reports about 11  -
HSD1 have shown that mRNA (Northern blot) and re-
ductase activity (from homogenates) are expressed in 
maternal derived decidua but not in fetal membranes 
 [29] . Surprisingly, subsequent studies demonstrated 
abundant 11  -HSD1 mRNA in chorion and small 
amounts in amnion as well as in placenta (no separation 
of decidua)  [10] . It was also shown that 11  -HSD1 protein 
is upregulated during pregnancy in the fetal membranes 
at term  [11] and that local PGF2  may contribute to the 
initiation of labor by increasing 11  -HSD1 reductase ac-
tivity to promote cortisol production  [12] .
 For 11  -HSD2 mRNA we found downregulated levels 
in fetal membranes and agree therefore with the results 
of Sun et al.  [10] who also missed 11  -HSD2 mRNA in 
fetal membranes. However, we found again little consis-
tency between mRNA and protein: the 11  -HSD2 pro-
tein was expressed in all layers. In our study, oxidase ac-
tivity was significantly higher in decidua and cotyledon 
than in fetal membranes. We could not find any differ-
ence in the oxidase activity between the two isoenzymes. 
Neither were we able to detect relevant 11  -HSD1 reduc-
tase activity in any studied tissue. Already McCalla et al. 
 [13] have shown absent reductase activity in homogenates 
of the whole placenta. However, in subsequent studies, 
reductase activity could be demonstrated in homogenates 
of separated placental tissue. It was therefore hypothe-
sized that in placenta (syncytiotrophoblast) and in de-
cidua both isoenzymes act as oxidase whereas in fetal 
membranes the 11  -HSD1 acts only as reductase  [11] .
 In cases of IUGR, we found upregulated 11  -HSD1 
mRNA in chorion but no superior protein level. Although 
an overall match in gestational age for the groups was care-
fully attained, we were unable to prevent that the IUGR 
group delivered up to 10 days earlier. It is unlikely that the 
higher level in chorion for the IUGR than for the control 
group is associated with the lower gestational age in that 
group. For 11  -HSD2 mRNA, we found downregulated 
levels in pregnancies with IUGR only in decidua and in 
cotyledon and agree therefore with results from studies 
performed with placental tissue (without fetal membranes) 
of IUGR that showed significantly depressed mRNA  [19, 
20] . However, we could not find reduced 11  -HSD2 pro-
tein levels whereas oxidase activity was also depressed in 
decidua and cotyledon. Other studies have shown a sig-
nificantly lower 11  -HSD2 activity in placental tissue from 
IUGR than from normal pregnancies  [10, 13, 21, 30] .
 To conclude, our results demonstrate the different con-
tribution of the two 11  -HSD isoenzymes on the level of 
mRNA, protein and activity in fetal/placental metabo-
lism. However, in cases of IUGR the oxidase activity of 
both isoenzymes is reduced in placenta. The underlying 
mechanism may be a post-transcriptional gene regulation 
relying on specific or different RNA-protein interactions 
in case of IUGR and in normal pregnancies respectively. 
The importance of these regulatory mechanisms is illus-
trated by the clinical relevance: epidemiological studies 
have linked low birth weight with the later occurrence of 
cardiovascular and metabolic disorders, particularly hy-
pertension  [1–4] . To provoke increasing activity with oxi-
dase stimulators could therefore be a future therapy in 
cases of IUGR preventing also complications such as car-
diovascular disorders in adult life. Otherwise, attention 
should be given in pregnancies with IUGR and the re-
quirement of glucocorticosteroids which additionally de-
crease the activity of the 11  -HSD. The most relevant 
therapy with glucocorticosteroids in obstetrics is that for 
fetal lung maturation in preterm labor, which could con-
sequently be a problem in pregnancies with IUGR.
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